Efficacy and Safety of Lumiracoxib

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This trial assessed the safety and efficacy of a single dose of lumiracoxib 400 mg compared to placebo and to a single dose of celecoxib 200mg. It also assessed safety and efficacy of 400mg lumiracoxib administered once a day for 7 days compared to placebo and to 200 mg celecoxib twice daily.

• Phase: Phase 3

Details

• Lead Sponsor: Novartis
• Treatments: Diclofenac; Lumiracoxib

Criteria

Inclusion criteria:

• Osteoarthritis of the knee

• Pain intensity at baseline of at least 50mm on a 100mm visual analog scale

Other protocol-defined inclusion/exclusion criteria may apply